HORSHAM, Pa., May 28 /PRNewswire/ -- Centocor Ortho Biotech Products, L.P. today announced that data related to several compounds will be presented at the 45th American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Fla., from May 29 to June 2, 2009. The studies were sponsored by Centocor Ortho Biotech Products, L.P. or its research partner, Ortho Biotech Oncology Research and Development, a unit of Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
“We are pleased that ASCO has accepted these data for presentation at their annual meeting,” said Thomas Schaible, Vice President, Medical Affairs, Centocor Ortho Biotech. “Through our ongoing investigation of key clinical compounds, Centocor Ortho Biotech is committed to advancing the understanding of the therapeutic options it offers to patients fighting cancer.”
Data from the following studies have been selected for presentation and posters:
Authors: J. J. Shah, A. Londhe, K. C. Lantz, C. Lowery, R. Z. Orlowski; University of Texas M. D. Anderson Cancer Center, Houston, TX; Centocor Ortho Biotech Services LLC, Horsham, PA
General Poster Session, Sunday May 31, 2:00 pm to 6:00 pm, Level 2, West Hall C
Authors: T. J. Herzog, J. B. Vermorken, E. Pujade-Lauraine, J. Li, E. Bayever, J. Gomez, A. Yovine, B. J. Monk; Columbia University Medical Center, New York, NY; University Hospital Antwerp, Antwerp, Belgium; Hopital Hotel-Dieu, Paris, France; Johnson & Johnson PRD, USA, Raritan, NJ; PharmaMar SAU, Colmenar Viejo, Madrid, Spain; University of California Irvine Medical Center, Orange, CA
General Poster Session, Sunday May 31, 2:00 pm to 6:00 pm, Level 2, West Hall C
Authors: A. Poveda, S. B. Kaye, R. T. McCormack, S. Wang, D. Ricci, E. Broderick, T. Parekh, C. Lebedinsky, J. C. Tecero, B. J. Monk; Instituto Valenciano de Oncologia, Valencia, Spain; The Royal Marsden Hospital, Sutton, United Kingdom; Ortho Clinical Diagnostics, Raritan, NJ; Ortho Biotech Oncology Research & Development, Raritan, NJ; PharmaMar SAU, Madrid, Spain; University of California Irvine Medical Center, Orange, CA
General Poster Session, Monday June 1, 8:00 am to 12:00 pm, Level 2, West Hall C
Authors: J. A. Berlin, P. J. Bowers, S. Rao, S. Sun, K. Liu, D. H. Henry; Johnson & Johnson PRD, Titusville, NJ; Johnson & Johnson PRD, Raritan, NJ; Pennsylvania Onc Hem Assoc, Philadelphia, PA
Poster Discussion, Monday June 1, 2:00 pm to 6:00 pm, Level 3, W340A
Discussion, Monday June 1, 5:00 pm to 6:00 pm, Level 2, West Hall F3
Authors: C. N. Krasner, A. Poveda, T. Herzog, J. Vermorken, B. Monk, P. Zintl, J. Li, Y. Su, R. Dhawan, S. Kaye; Massachusetts General Hospital, Boston, MA; Fundacion Instituto Valenciano de Oncologia, Valencia, Spain; Columbia University Medical Center, New York, NY; Universitair Ziekenhuis Antwerpen, Edegem, Belgium; Chao Family Comprehensive Cancer Center UC, Orange, CA; PharmaMar SAU, Madrid, Spain; Johnson & Johnson, Raritan, NJ; Royal Marsden Hospital, Sutton, United Kingdom
About DOXIL(R) (doxorubicin HCl liposome injection)
DOXIL is indicated for the treatment of patients with ovarian cancer whose disease has progressed or recurred after prior platinum based therapy. DOXIL in combination with VELCADE(R) (bortezomib) is indicated for the treatment of patients with multiple myeloma who have not previously received VELCADE and have received at least one prior therapy. DOXIL is also indicated for the treatment of AIDS-related Kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy.
IMPORTANT SAFETY INFORMATION
BOXED WARNINGS:
Cardiotoxicity, infusion reaction, myelosuppression, liver impairment, substitution
Contraindications
Additional Safety Information
Please see accompanying full Prescribing Information, including Boxed WARNINGS.
DOXIL is marketed in the United States by Centocor Ortho Biotech Products, L.P., and in Israel by Janssen-Cilag. Schering-Plough Corporation, under a licensing agreement, has exclusive rights to market the medication as CAELYX throughout the rest of the world, excluding Japan and Israel. For more information about DOXIL, please visit www.DOXIL.com.
About PROCRIT (Epoetin alfa)
PROCRIT is used for the treatment of anemia in patients with most types of cancer receiving chemotherapy, with chronic renal failure who are on dialysis and those who are not on dialysis, who are being treated with zidovudine for HIV infection, and to reduce the need for transfusion in anemic patients who are scheduled for elective noncardiac, nonvascular surgery. Depending on the country in which Epoetin alfa is marketed, these indications may differ.
Important Safety Information
WARNINGS: Increased Mortality, Serious Cardiovascular and Thromboembolic Events, and increased risk of tumor progression OR recurrence
Renal failure: Patients experienced greater risks for death and serious cardiovascular events when administered erythropoiesis-stimulating agents (ESAs) to target higher versus lower hemoglobin levels (13.5 vs. 11.3 g/dL; 14 vs. 10 g/dL) in two clinical studies. Individualize dosing to achieve and maintain hemoglobin levels within the range of 10 to 12 g/dL.
Cancer:
Perisurgery: PROCRIT (Epoetin alfa) increased the rate of deep venous thromboses in patients not receiving prophylactic anticoagulation. Consider deep venous thrombosis prophylaxis.
Contraindications
Additional Important Safety Information
Please visit www.procrit.com for the full Prescribing Information, including the Boxed WARNINGS, and for the Medication Guide and Patient Instructions for Use.
About Trabectedin
Trabectedin is a novel cytotoxic antitumor agent that was originally derived from the Caribbean tunicate, Ecteinascidia turbinate (“sea squirt”). The compound is now produced synthetically. Trabectedin binds to the minor groove of DNA, interfering with cell division and genetic transcription processes and DNA repair machinery. Trabectedin is currently in Phase 3 development in ovarian cancer and to expand its uses in sarcoma.
According to the licensing agreement, PharmaMar SAU has rights to market the compound in Europe and Japan, while Centocor Ortho Biotech Products, L.P. has marketing rights for the product in the rest of the world.
About Centocor Ortho Biotech Products, L.P.
Centocor Ortho Biotech redefines the standard of care in immunology, nephrology, and oncology. The company was formed when Centocor, Inc. and Ortho Biotech Products, L.P. were consolidated in late 2008, and was renamed Centocor Ortho Biotech. Built upon a pioneering history, Centocor Ortho Biotech harnesses innovations in large-molecule and small-molecule research to create important new therapeutic options. Beyond its innovative medicines, Centocor Ortho Biotech is at the forefront of developing education and public policy initiatives to ensure patients and their families, caregivers, advocates, and healthcare professionals have access to the latest treatment information, support services, and quality care.
Note: This release corresponds to ASCO abstracts 5526, 5550, 5551, 8591 and 9625
CONTACT: Lisa Vaga, +1-908-218-7316, Mobile: 908-670-0363,
lvaga@its.jnj.com
